Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience-Reference-Cited by-同舟云学术

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience

Published:2020-07-14 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Wu Pei-Ying,Cheng Ya-Min,Shen Meng-Ru,Chen Yi-Chun,Huang Yu-Fang,Chou Cheng-Yang

Funder

Ministry of Education

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference34 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin.,2018

2. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Cancer.,2019

3. Prognostic factors in epithelial ovarian cancer: a population-based study;Chang;PLoS ONE.,2018

4. PARP inhibitors in ovarian cancer;Franzese;Cancer Treat Rev.,2019

5. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials;Jiang;Medicine.,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Urine Protein to Creatinine Ratio for the Assessment of Bevacizumab-Associated Proteinuria in Patients with Gynecologic Cancers: A Diagnostic and Quality Improvement Study;Diagnostics;2024-08-24

2. Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology;International Journal of Molecular Sciences;2024-03-10

3. Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent Ovarian Cancer;In Vivo;2023-12-25

4. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis;Biomedicine & Pharmacotherapy;2023-07

5. Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics;Future Oncology;2023-05